StockGuru Leader Board: Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) Closed Up 42.54% on Monday

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) is on The StockGuru Leader Board today.  The stock closed up 42.54% on Monday.

Volume was 3,356,562 shares traded.

Join in on the Discussion about AMPE

About the Company:

Ampio Pharmaceuticals, Inc., a development stage pharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Optina, an orally administered compound that is in Phase II clinical trial for the treatment of diabetic retinopathy, diabetic macular edema, and hereditary angioedema; Vasaloc for the treatment of diabetic nephropathy; Zertane, an oral drug in late stage development that treats male sexual dysfunction for premature ejaculation; and Ampion, a non-steroidal biologic, aspartyl-alanyl diketopiperazine to treat chronic inflammatory and autoimmune diseases. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact:
IR Affiliates –
StoneBridge Web & SEO –

All content on is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070